`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`––––––––––
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`––––––––––
`
`ELEKTA INC.
`Petitioner
`v.
`
`VARIAN MEDICAL SYSTEMS, INC.
`Patent Owner
`
`––––––––––
`
`Case IPR2016-01902
`Patent No. 6,888,919
`
`––––––––––
`
`ELEKTA INC.’S AND VARIAN MEDICAL
`SYSTEMS, INC.’S JOINT MOTION TO
`TERMINATE PROCEEDING PURSUANT
`TO 35 U.S.C. § 317 AND 37 C.F.R. § 42.74
`
`
`
`
`
`
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box. 1450
`Alexandria, Virginia 22313-1450
`
`
`
`
`
`Case IPR2016-01902
`U.S. Patent No. 6,888,919
`Pursuant to 35 U.S.C. § 317(a) and 37 C.F.R. § 42.74(a), and the Board’s
`
`Order Authorizing Motion to Terminate, Paper No. 11 (April 7th, 2017), Patent
`
`Owner Varian Medical Systems, Inc. (“Patent Owner”) and Petitioner Elekta Inc.
`
`(“Petitioner”) jointly move to terminate the present inter partes review proceeding,
`
`in light of Patent Owner’s and Petitioner's (hereinafter Patent Owner and Petitioner
`
`are referenced as “the parties”) resolution of their dispute relating to U.S. Patent No.
`
`6,888,919 (the “’919 Patent”).
`
`Termination is appropriate in the instant proceeding because the dispute
`
`between the parties has been resolved and because full termination would encourage
`
`settlement of Patent Office proceedings, consistent with federal judicial preference
`
`and the management of limited judicial and Patent Office resources.
`
`As required by 35 U.S.C. § 317(b), the parties are filing, concurrently
`
`herewith, a true copy of their Settlement Agreement (executed on April 3rd, 2017) as
`
`Exhibit 2007.1 Pursuant to Paragraph 6.2 of the Settlement Agreement, Patent Owner
`
`and Petitioner jointly agreed to terminate this proceeding. Accordingly, the parties
`
`jointly request that this proceeding be terminated under 35 U.S.C. § 317(a) and 37
`
`C.F.R. § 42.74. See Fandango, LLC et al. v. Ameranth, Inc., CBM2014-00013, Paper
`
`22, pp. 5-6 (PTAB March 24, 2014). There are no additional collateral agreements or
`
`
`1 The Settlement Agreement has been filed electronically via E2E for “Parties and
`
`Board Only” to preserve confidentiality.
`
`
`
`2
`
`
`
`
`
`Case IPR2016-01902
`U.S. Patent No. 6,888,919
`understandings made in connection with, or in contemplation of, termination of the
`
`inter partes review. The parties have stipulated to dismiss the related litigation
`
`involving the ’919 Patent in Varian Medical Systems v. Elekta AB et al., No. 15-871-
`
`LPS, in the United States District Court for the District of Delaware. The parties are
`
`also submitting a joint motion to terminate proceedings in another inter partes
`
`review involving the ’919 Patent, Elekta Inc. v. Varian Medical Systems, Inc., Case
`
`No. 2016-01904. No litigation or proceeding between the parties involving the ’919
`
`Patent is contemplated in the foreseeable future.
`
`Under 35 U.S.C. § 317(a), “[a]n inter partes review instituted under this
`
`chapter shall be terminated with respect to any petitioner upon the joint request of the
`
`petitioner and the patent owner, unless the Office has decided the merits of the
`
`proceeding before the request for termination is filed.” This proceeding has been
`
`instituted; however, no Patent Owner Response has been filed and the Board has not
`
`decided on the merits of the proceeding.
`
`Strong public policy considerations favor settlement between the parties to an
`
`inter partes review proceeding. See Office Trial Practice Guide, Fed. Reg., Vol. 77,
`
`No. 157 at 48768 (Aug. 14, 2012). No public interest or other factors weigh against
`
`termination of this proceeding.
`
`Further, both Congress and federal courts have expressed a strong interest in
`
`encouraging settlement in litigation. See, e.g., Delta Air Lines, Inc. v. August, 450
`
`U.S. 346, 352 (1981) (“The purpose of [Fed. R. Civ. P.] 68 is to encourage the
`3
`
`
`
`
`
`
`Case IPR2016-01902
`U.S. Patent No. 6,888,919
`settlement of litigation.”); Bergh v. Dept. of Transp., 794 F.2d 1575, 1577 (Fed. Cir.
`
`1986) (“The law favors settlement of cases.”), cert. denied, 479 U.S. 950 (1986). The
`
`Federal Circuit places a particularly strong emphasis on settlement. For example, it
`
`endorses the ability of parties to agree to never challenge validity as part of a
`
`settlement. See Flex-Foot, Inc. v. CRP, Inc., 238 F.3d 1362, 1370 (Fed. Cir. 2001);
`
`see also Cheyenne River Sioux Tribe v. U.S., 806 F.2d 1046, 1050 (Fed. Cir. 1986)
`
`(noting that the law favors settlement to reduce antagonism and hostility between
`
`parties).
`
`Maintaining this review after the parties reach a settlement would discourage
`
`future settlements by removing a primary motivation for settlement: eliminating
`
`litigation risk by resolving the parties’ disputes and ending the pending proceedings
`
`between them. For patent owners, litigation risks include the potential for their
`
`patents to be invalidated. If a patent owner knows that an inter partes review is likely
`
`to continue regardless of settlement, it can create a strong disincentive for the patent
`
`owner to settle.
`
`Further, one of the primary reasons courts endorse settlement is preservation
`
`of judicial resources. Maintaining this review after the parties have settled their
`
`disputes would waste, rather than conserve, judicial resources. For example, in the
`
`event the Board finds some of the subject claims unpatentable, Patent Owner would
`
`be entitled to an appeal to the Federal Circuit. As the only party remaining in the
`
`
`
`4
`
`
`
`
`
`Case IPR2016-01902
`U.S. Patent No. 6,888,919
`case, the Office would have to defend the Board’s decision, which would further
`
`waste valuable judicial and administrative resources.
`
`The parties further request, pursuant to 37 C.F.R. § 42.74(c), that the
`
`agreement (Ex. 2007) be treated as confidential business information and kept
`
`separate from the files of the involved patent. The parties are filing, concurrently
`
`herewith, a Joint Request to File the Settlement Agreement as Business Confidential
`
`Information pursuant to 35 U.S.C. § 317 and 37 C.F.R. § 42.74(c). For the foregoing
`
`reasons, the parties jointly and respectfully request that the instant proceeding be
`
`terminated.
`
`
`Respectfully submitted this 12th day of April, 2017.
`
`
`
`/Eliot D. Williams/
`Eliot D. Williams
`Reg. No. 50,822
`Baker Botts L.L.P.
`1001 Page Mill Road
`Building One, Suite 200
`Palo Alto, California 94304
`Phone: (650) 739-7511
`E-mail: eliot.williams@bakerbotts.com
`Lead Counsel for Patent Owner
`
`/Timothy J. May/
`Timothy J. May
`Reg. No. 41,538
`Finnegan, Henderson, Farabow, Garrett &
`Dunner, LLP
`5
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2016-01902
`U.S. Patent No. 6,888,919
`901 New York Avenue, NW
`Washington, DC 20001
`Phone: (202) 408-4000
`E-mail: tim.may@finnegan.com
`Lead Counsel for Petitioner
`
`6
`
`
`
`Case IPR2016-01902
`U.S. Patent No. 6,888,919
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. §§ 42.6(e), I hereby certify that on April 12, 2017
`
`the foregoing document is being served electronically by agreement of the
`
`parties, by e-mail to the following counsel of record:
`
`
`
` tim.may@finnegan.com
`Timothy J. May
`James R. Barney james.barney@finnegan.com
`Lauren J. Dreyer lauren.dreyer@finnegan.com
`Joshua L. Goldberg joshua.goldberg@finnegan.com
`
`Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001
`(202) 408-4000
`
`
`/Eliot D. Williams/
`
`
`
`
`
`
`
`
`7
`
`
`
`
`
`